On-site bundled rapid HIV/HCV testing in substance use disorder treatment programs: study protocol for a hybrid design randomized controlled trial

Jemima A. Frimpong1*, Thomas D’Aunno2, David C. Perlman3, Shiela M. Strauss4, Alissa Mallow5, Diana Hernandez6, Bruce R. Schackman7, Daniel J. Feaster8 and Lisa R. Metsch6

Abstract

Background: More than 1.2 million people in the United States are living with human immunodeficiency virus (HIV), and 3.2 million are living with hepatitis C virus (HCV). An estimated 25% of persons living with HIV also have HCV. It is therefore of great public health importance to ensure the prompt diagnosis of both HIV and HCV in populations that have the highest prevalence of both infections, including individuals with substance use disorders (SUD).

Methods/design: In this theory-driven, efficacy-effectiveness-implementation hybrid study, we will develop and test an on-site bundled rapid HIV/HCV testing intervention for SUD treatment programs. Its aim is to increase the receipt of HIV and HCV test results among SUD treatment patients. Using a rigorous process involving patients, providers, and program managers, we will incorporate rapid HCV testing into evidence-based HIV testing and linkage to care interventions. We will then test, in a randomized controlled trial, the extent to which this bundled rapid HIV/HCV testing approach increases receipt of HIV and HCV test results. Lastly, we will conduct formative research to understand the barriers to, and facilitators of, the adoption, implementation, and sustainability of the bundled rapid testing strategy in SUD treatment programs.

Discussion: Novel approaches that effectively integrate on-site rapid HIV and rapid HCV testing are needed to address both the HIV and HCV epidemics. If feasible and efficacious, bundled rapid HIV/HCV testing may offer a scalable, potentially cost-effective approach to testing high-risk populations, such as patients of SUD treatment programs. It may ultimately lead to improved linkage to care and progress through the HIV and HCV care and treatment cascades.

Trial registration: ClinicalTrials.gov: NCT02355080. (30 January 2015)

Keywords: HIV testing, HCV testing, Bundled HIV/HCV testing, Hybrid intervention-implementation research, Intervention adaptation, Substance use disorder treatment, Adoption of evidence-based practices, Implementation research

* Correspondence: jf2584@columbia.edu
1Department of Health Policy and Management, Mailman School of Public Health, Columbia University, New York, USA
Full list of author information is available at the end of the article

© 2016 Frimpong et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
More than 1.2 million people in the United States are living with HIV, with an estimated 50,000 persons newly infected each year [1]. Approximately 3.2 million people are chronically infected with HCV [2, 3]. HIV/HCV co-infection is common: up to 25 % of the people infected with HIV in the US also have HCV [4, 5]. The prevalence of HIV and HCV in the US is particularly high among persons with substance use disorders (SUDs). Approximately, 25 % of HIV/AIDS cases are directly or indirectly related to injection drug use, [6] and the prevalence of HCV among people who inject drugs (PWID) ranges from 35 to 65 % [2, 7, 8]. HIV and HCV are also common among persons who use but do not inject drugs (for example, intranasal use of cocaine or heroin) [9]. Among those infected with HIV and/or HCV, significant numbers of people are not aware of their infection and are 1) more likely to transmit infection(s); 2) less likely to benefit from early treatment; and 3) more prone to morbidity, mortality, and complications due to co-infection [10–12]. The Centers for Disease Control and Prevention (CDC) recommend routine HIV and HCV testing for people with a history of drug use [13–15].

The availability of both HIV and HCV testing in SUD treatment programs is limited. Fewer than half of U.S. SUD treatment programs offer HIV testing on-site to their patients [10, 16–20]. The availability of on-site HCV testing even declined from 53 % in 2005 to 34 % in 2011 in opioid treatment programs [21]. The limited availability of on-site testing is related to gaps in the capacity of SUD treatment programs to conduct laboratory-based HIV or HCV testing. [18, 22] In recent years, SUD treatment programs have increasingly offered off-site referrals for HIV and/or HCV testing to their patients, instead of incurring large fixed costs required to make laboratory-based HIV testing available on-site [23, 24]. In addition, laboratory-based HIV or HCV testing methods do not produce immediate results, and thus require patients to return to the clinic for their test results. Unfortunately, few patients follow up on referrals for off-site testing [24, 25] or return for their test results [26–29].

Rapid testing assays, introduced more than 10 years ago for HIV and in 2010 for HCV, have the potential to address several of these barriers to the scale up of HIV/HCV testing in SUD treatment programs [30–32]. Rapid tests for HIV and HCV use blood from a finger stick or oral fluid from a swab and can be conducted under a Clinical Laboratory Improvement Agreement (CLIA) Certificate of Waiver. [33] They do not require extensive laboratory facilities and can be performed without a doctor, nurse, or phlebotomist. They are also highly accurate [26, 31, 34] and yield preliminary results in no more than 20 minutes, which allows testing and result notification to occur during the same visit.

Despite several calls for the integration of HIV and HCV services [35–41], SUD treatment programs have not yet adopted a rapid HIV/HCV testing “bundle” for several reasons [26]. First, offering both tests might be time consuming for staff that already faces a significant workload. Offering on-site bundled HIV/HCV testing thus requires streamlined testing procedures to facilitate integration and reduce constraints on service delivery. Second, some patients may become particularly dis- tressed if they learn that they are infected with both HIV and HCV in the same visit. Post-test counseling procedures adapted to the provision of bundled testing must therefore be developed. Third, in the past, HCV treatments were arduous, ineffective, and associated with serious side effects. The recent introduction of new, safe, and highly efficacious treatment options for HCV address these issues [42] and suggest that HCV testing may now present significantly more clinical benefits to patients. Fourth, treatments for HCV remain expensive. However, increased access to health insurance through the Affordable Care Act (ACA) [43] may present opportunities for increasing access to HCV treatment and care for persons with SUDs who may have previously lacked health insurance [44, 45].

Study objective
The overarching objective of this study is to develop and test an on-site bundled rapid HIV and HCV testing strategy to facilitate the timely diagnosis and receipt of test results for both HIV and HCV among persons with SUDs.

Methods/design
Study design
This efficacy-effectiveness-implementation hybrid study consists of three distinct phases. Hybrid study designs combine features of clinical trials, which examine the efficacy, effectiveness, and the implementation research, which examines the adoption and sustainability of service delivery processes [46, 47]. Hybrid designs are postulated to advance the adoption and use of evidence-based practices and enhance the potential benefits of effective interventions [48–50]. In the “developmental phase” of this study, we will produce a protocol for the provision of on-site bundled rapid HIV/HCV testing in SUD treatment programs. This will be followed by a “trial” phase, during which we will test the efficacy of the on-site bundled rapid HIV/HCV testing approach in increasing receipt of HIV and HCV test results among SUD patients. Finally, during a “translation” phase, we will conduct formative research on the barriers and facilitators of the diffusion, adoption, implementation, and sustainability of on-site bundled rapid HIV/HCV testing in SUD treatment programs. Overall, we will develop and evaluate the efficacy of the bundled rapid testing
intervention and explore the preliminary effectiveness and implementation considerations related to intervention scale up. This study protocol follows the SPIRIT statement (http://www.spirit-statement.org/spirit-statement/).

**Conceptual/theoretical framework**
To guide our approach to “bundling” the offer of on-site rapid HIV and rapid HCV testing, we use an enhanced version of ADAPT-ITT, [51–53] a framework used to transfer evidence-based HIV interventions (HIV EBIs) to new relevant populations. ADAPT-ITT builds on a sequence of Assessment-Decision-Administration-Production-Topical experts (ADAPT) -Integration-Training-Testing (ITT) and culminates in a rigorous randomized controlled trial of the impact of the newly developed intervention on short-term outcomes (for example, receipt of HIV and HCV test results). Because we use ADAPT-ITT to add a multi-infection component to existing HIV EBIs, rather than to transfer EBIs across relevant populations, we modify some of the framework’s procedures. The “decision” phase of ADAPT-ITT is replaced by a “design” phase, during which we will address key questions related to the structure and content of the testing session. We also enhance the training component of the model by integrating a standardized patients (SP) approach, an objective structured clinical education procedure for training, evaluating and providing feedback to providers to ensure the effective completion of clinical tasks [54, 55].

To enable a broad scale up of on-site bundled HIV/HCV testing, we add a final “translational” step to the ADAPT-ITT process. We refer to this extended framework as “ADAPT-IT^3.” Our translational approach is guided by a rich, interdisciplinary understanding of the “Diffusion of Innovation” (DOI) theory outlined by Rogers [56, 57]. DOI is defined as the process through which an innovation is spread over time via communication (information, attitudes, etcetera) among members of a social system (patients and organizations) [57]. The goal of DOI is to advance an innovation from adoption, through implementation, to routinizing [56, 58, 59]. Rogers describes two separate DOI processes: one for organizations and another for individuals. This is in contrast to current practice in healthcare organizations, where new interventions or services are often developed solely by matching the proposed innovation to the work needs and characteristics of its intended users [60]. DOI theory, on the other hand, emphasizes the complexity of communication channels and structural aspects of a social system in establishing the conditions that will favor DOI. The details of the ADAPT-IT^3 process are described in Table 1, with the DOI framework for organizations and individuals described in Table 2. We detail the key steps of the implementation of the proposed randomized controlled trial below.

**Study facilities and setting**
The study will be conducted at Promesa Inc. of the Acacia Network, one of the largest community based SUD treatment programs in the Bronx in New York City [61]. It has the capacity to serve more than 1,700 patients at any point in time across all of its facilities. We will include (1) one facility, which provides methadone to abstinence treatment to patients with opioid dependence (methadone-to-abstinence ambulatory - MTAA). Methadone to abstinence is a medical treatment protocol where methadone is provided in gradually decreasing doses until the point of abstinence. We will also include (2) one facility, which provides behavioral treatments (for example, cognitive behavior approaches) to patients with addictions to opioids and other types of drugs (chemical dependence outpatient program – CDOP). Both MTAA and CDOP are co-located with a federally qualified health center that provides primary healthcare services. The Primary Care Health Center (PCHC) offers on-site laboratory-based enzyme immuno-assay (EIA) HIV and HCV testing with delayed results. SUD treatment patients who test positive for either HIV or HCV are referred to relevant medical services. Typically, patients choose to stay in the FQHC co-located with MTAA and CDOP, but if they prefer, they can be referred to another FQHC or primary care health center of their choice.

**Existing evidence-based rapid HIV testing interventions**
Our starting point for the development of the on-site bundled rapid HIV/HCV testing intervention is grounded on existing HIV EBIs, which address testing procedures and linkages to care. The rapid HIV testing EBI we will adapt was shown to be highly effective in increasing receipt of HIV test results compared to referral for off-site HIV testing (80 % versus 18 %, respectively) [25]. Patients in this EBI first receive verbal information about the rapid HIV test, including a description of the rapid testing procedure, timing for and meaning of test results, and an explanation of the window period during which an antibody test might be negative despite the presence of HIV infection. Patients are then offered a rapid HIV test [62]. Our approach to linkage to care services will be based on a modified Anti-retroviral Treatment and Access to Services (ARTAS) and Hepatitis C Care Coordination Model (Hep-C CCM) [63–66]. ARTAS is an individual-level, multisession, time-limited intervention with the goal of linking recently diagnosed persons with HIV to medical care soon after receiving a positive test result. ARTAS led to significantly higher linkage to HIV care compared to a “passive referral” standard of care [63, 64]. Hep-C CCM is a case manager-coordinated service that links patients to primary care and hepatology clinics. The intervention was efficacious in increasing both attendance at HCV clinical evaluations and...
knowledge of HCV [65, 66]. The protocol for on-site bundled rapid HIV/HCV testing will incorporate elements from these interventions. It will be developed through a combination of in-depth interviews, focus group discussions, interactive testing, and expert consultations (see Table 1).

### Study intervention

Patients randomized to the intervention group will thus receive an offer to participate in on-site bundled rapid HIV/HCV testing. Those who accept this offer will receive pre-test information about testing procedures and education, be tested and receive results during the same visit as testing, and be provided post-test counseling and support services according to the protocol developed through our ADAPT-IT³ process. Patients with reactive HIV and/or HCV antibody test results will be actively linked immediately to a healthcare provider for further evaluation and confirmatory testing (see Fig. 1).

### Patients randomized to the control group will receive the standard of care (SOC). The SOC is venipuncture whole blood laboratory-based HIV and HCV testing with

---

### Table 1 Study design and overview of approach to on-site bundled rapid HIV and HCV testing

| ADAPT-IT³ Steps (Intervention Development) | Participants | Data Collection | Method | Output |
|--------------------------------------------|--------------|----------------|--------|--------|
| (1) Assessment                             | 30 to 40     | Focus groups   | Focus group discussion with patients and providers separately. Capacity assessment with program managers | Not applicable (n/a) |
| (2) Design                                 | n/a          | n/a            | Investigative team reviews assessment data and then devises preliminary approach to developing and refining bundled rapid HIV/HCV testing procedures. | Draft protocol 0 of intervention |
| (3) Administration                         | 10           | 2-4            | Mock intervention is implemented in front of selected patients and providers (from step 1). | Draft protocol 0 of intervention |
| (4) Production                             | n/a          | n/a            | Exit survey follows performance, informs open discussion about modification. | Draft protocol 1 of intervention |
| (5) Topical experts                        | n/a          | n/a            | Investigative team incorporates feedback from theater tests into testing algorithm and manual, develops quality assurance plan. | Draft protocol 1 of intervention |
| (6) Integration                            | n/a          | n/a            | Integrate content from patient/program advisors, and topical experts. | Draft protocol 2 of intervention |
| (RCT) Training                             | n/a          | 2 to 4         | Train program and study staff to implement draft protocol. | Draft protocol 2 of intervention |
| (8a) Testing (Pilot)                       | 20           | 2 to 4         | Pilot with patients who are representative of target population. Feedback through exit interviews with patients, and feedback from managers and providers who observed the pilot. Produce draft three based on pilot. Refresher training, as appropriate, for program and study staff on draft three of the intervention protocol. | Draft protocol 3 of intervention |
| (8b) Testing (RCT)                         | 239          | 2 to 4         | Test draft three of the protocol. Analyze RCT results to determine efficacy. | Assessment of study outcomes |
| (TRANSLATION) (9) Translation              | 20 to 30     | Focus groups   | Elicit reactions of RCT participants. Classify perceived barriers/facilitators to acceptance of bundled rapid testing, referral, and linkage services (patients); and adoption of bundled rapid testing and linkage services (providers and managers). | Multilevel diffusion strategy |
delayed results (enzyme immunoassay). Patients may not receive pre-test information, results, and post-test counseling, especially if non-reactive or negative test result(s). Linkage to care in the SOC is accomplished by referral to a healthcare provider within the participating SUD treatment organization or by passive referral to other health facilities. After the end of the follow-up period (see below), all patients in the control group will be offered access to the on-site bundled rapid HIV/HCV testing intervention. This will include all procedures (that is, rapid HIV/HCV testing, post-test counseling, and linkages to care), as appropriate. Trained study staff will obtain written informed consent from all patients prior to enrollment. Additionally, trained supervisors will monitor the safety and efficacy of the trial intervention on a regular basis. They will ensure that all study procedures are conducted and that data are generated, documented, and reported in compliance with the protocol and applicable regulations.

**Randomization**
Participants will be assigned randomly to the intervention or to the control group at the time of the baseline visit. Randomization will be stratified by recruitment site (MTAA versus CDOP programs), location of primary care provider (study site versus other), and type of drug use (injection as a method of drug use versus non-injection drug use). The randomization will be done in blocks of randomized size (varying from four to 10) with computer-generated random numbers. This procedure ensures that the distribution of treatment site and type of drug use will be balanced across intervention and control groups. It also prevents study staff from learning the randomization pattern, which becomes obvious in a fixed block-size scheme. The study statistician will generates the randomization lists, which will be concealed in sequentially numbered, opaque, sealed envelopes with a signature across the sealing point. Trained research assistants, who are blind to the randomization schedule, will provide the random assignment to participants at the time of randomization.

**Eligibility and recruitment**
Participants must be (1) able and willing to provide informed consent, (2) seeking or currently receiving SUD treatment services (excluding alcohol only) at the participating treatment programs, (3) at least 18 years old, (4) able to communicate in English, (5) willing to sign a release form that will allow medical record review (to corroborate self-reports of receipt of test results), (6) willing to provide locator information, (7) self report being HIV and HCV negative, or report not knowing their
HIV and HCV status, and (8) not have received results of an HIV or HCV test initiated within the last 12 months. We will employ several recruitment strategies to facilitate enrollment to reach our target sample size, including trained research staff, posters, and collaborating with staff of the study site to identify interested patients. We will promote participant retention by collecting locator information, which will be used to contact participants to remind them of follow-up visits and to locate participants who cannot be reached. Participation in the study is voluntary, and participants may choose to end their involvement at any time.

Study assessments
There will be three assessments during this trial of on-site bundled rapid HIV/HCV testing. These will include a baseline assessment administered prior to randomization, a follow-up assessment conducted 1 month after randomization, and a final assessment conducted 3 months after randomization (see Fig. 1).

Primary outcome
The primary outcome will be self-reported receipt of HIV and HCV test results. The primary outcome will be assessed one-month post-randomization. Our use of self-reported receipt of test results is consistent with the use of self-reports as the primary outcome for evaluating rapid HIV testing interventions [25].

Secondary outcome and other study measures
We will also evaluate several secondary outcomes. These will include an additional measure of receipt of test results based on medical records. Study participants will complete release forms (as applicable) in order to grant permission to study staff to review their medical records, including HIV and HCV testing records. Other secondary outcomes will include self-reported sexual risk behaviors and drug use practices such as (i) counts of unprotected vaginal and anal sex acts in the past 3 months with any sex partner, (ii) use of any drugs in the past 3 months, and (iii) unsafe injection practices. Additional measures will evaluate linkage to care by measuring the proportion of patients who initiated HIV care or HCV care before the 3-month follow-up among those whose test results were positive for HIV and/or HCV. Linkage to care for HIV or HCV will be measured separately, to account for variations in barriers to

---

Fig. 1 Flow diagram of the trial design: on-site bundled rapid HIV/HCV testing randomized controlled trial (RCT). The diagram illustrates the progression of participants through the different points of the study.
initiating care, which may be greater for HCV than barriers to initiating HIV medical care [67].

Data sources
In order to measure all outcomes, indicators, and covariates, each study assessment will collect detailed data from study participants. We will use audio computer-assisted self-interview (ACASI) to limit social desirability biases in reporting sensitive behaviors (for example, sexual behaviors) [68]. Interviewers will be trained in the use of the ACASI program and survey to assist respondents as needed. To protect against the risk of loss of confidentiality during and after the trial, all data will be maintained on a password-protected local server. Study datasets will be de-identified prior to analysis.

We will collect the following information:

Demographic characteristics of participants (at baseline), which will include age, sex, race and ethnicity, years of formal education, income, employment status, health insurance, living arrangement including homelessness, number of children (under 18), and history with the criminal justice system (that is, arrests and incarcerations). This information will be used to describe the study sample, to assess for any differences between intervention groups, and to test for selective attrition.

Sexual behaviors: We will collect data on the total number of sex partners in the past 3 months, total number of vaginal sex partners and anal sex partners, total number of unprotected vaginal and total number of anal sex partners, and total acts of unprotected vaginal/anal sex.

Drug use: We will ask about the frequency, duration, and amount of substance use, including alcohol, cannabis, methamphetamine, cocaine, heroin, club-drugs, and misused prescription drugs. We will assess injection drug use, including the types of drugs injected and the sharing of needles and other drug paraphernalia (for example, spoons and cotton balls). We will also ask about overdoses and treatment for overdose (that is, the use of naloxone). At baseline, we will measure these behaviors over the 3 months before the interview. These measures will be repeated at 1- and 3-month follow-ups, with adjustments to the recall period.

Utilization of drug treatment services: We will ask the following three questions at baseline and at both follow-up visits: (1) Are you in treatment right now? (2) What treatment are you undergoing? (for example, detox) and (3) How many days have you been in this treatment?

Linkage to medical care: We will also collect data on initiation of treatment among HIV and/or HCV positive patients, using the following questions: (1) Did you have an appointment with a medical provider for HIV services? (2) Did you have an appointment with a medical provider for HCV services? (3) Number of medical appointments made and appointments attended since the last interview, as well as initiation of ART and HCV treatment.

Power and sample size
We designed the trial to estimate the effects of on-site bundled rapid HIV/HCV testing on receipt of test results separately in each of the two types of SUD treatment facilities (MTAA and CDOP). Based on preliminary data from the study sites for the standard of care, we assumed that 50 % of control group participants enrolled at the CDOP facility will receive their HIV and HCV results after 1 month. We assumed that 45 % of control group participants receive their HIV and HCV test results after 1 month in the MTAA program, which treats a higher proportion of PWIDs. Based on findings from the evidence-based rapid HIV intervention that informs this study [25], we assumed that 80 % of patients in the intervention group would receive their HIV and HCV test results within 1 month of randomization. To detect such intervention effects on the basis of a two-sample, chi-squared test for independent proportions with 80 % power and \( \alpha = 0.05 \), we will require 78 patients in CDOP and 99 patients in MTAA facilities. We assumed an 80 % follow-up rate among participants enrolled at the MTAA program. We assumed a slightly lower follow-up rate among participants enrolled at the CDOP facility (75 %) because adherence to behavioral SUD treatment is lower among CDOP patients at Promesa Inc. These are conservative assumptions. For example, during the trial of the rapid HIV testing EBI, which informs this study, researchers achieved a 98 % 1-month follow-up rate [25]. In total, we obtained a total sample size of 239 participants (104 in CDOP and 135 in MTAA).

Empirical analysis
The primary outcome is a categorical variable denoting self-reported receipt of rapid HIV and rapid HCV test results at 1-month post-randomization. We will use a generalized estimating equation model, which includes covariates for type of drug use (injection/non-injection) and location of primary care provider (study site versus elsewhere). The model will also include indicator variables for HIV/HCV testing intervention status and the type of SUD treatment facility (MTAA versus CDOP), where the participants were recruited. The primary test of our study hypothesis will be a two-degree of freedom test of significance of the intervention across the two types of SUD treatment facilities. In post-hoc tests, the efficacy and effect size in each type of SUD treatment facility will be examined. To do so, we will include an interaction between variables identifying study groups (intervention versus control) and type of SUD treatment facility (MTAA versus CDOP). The primary analysis will be intent-to-treat, where everyone is included in the study.
group to which they were randomized, regardless of receipt of intervention. In sensitivity analyses, participants who have died or who have been lost to follow-up will be counted as not having tested. We will adjust for baseline covariates that may be associated with attrition from the study sample using inverse probability reweighting procedures as recommended for the GEE model [69].

The secondary outcomes related to linkage to HIV and HCV care, as well as to drug use, are categorical variables. They will be analyzed using techniques similar to those used for the primary outcome. This is also the case for indicators related to HIV and HCV prevalence among patients tested by bundled rapid testing versus standard of care. The number of unprotected sex acts over a period of time is a count variable and will be modeled using Poisson or negative binomial regression (if the variable is over-dispersed) or the zero-inflated version of these if necessary. Type of drug use (injection/non-injection) and the recruitment site (MTAA or CDOP) will be included as covariates. If other covariates predict missing data, they will also be included as control variables. All analyses of secondary outcomes will focus on the pooled data, that is, CDOP + MTAA programs. Because of the limited sample size, we will not conduct formal mediation analyses.

Translation
We will conduct formative research on the barriers and facilitators of the adoption, implementation, and sustainability of on-site bundled rapid HIV/HCV testing in SUDs treatment programs. To do so, we will collect qualitative data from three groups: patients, providers, and program managers who participated in the randomized trial. This will consist of two focus group discussions (FGDs) with each group, followed by a short questionnaire on individual perceptions. FGDs will be informed by an integrated conceptual framework, derived from the “Diffusion of Innovation” theory [56]. We will identify facilitators and barriers to scaling-up the bundled rapid HIV/HCV strategy, linking infected patients to medical care, and we will develop strategies to address these barriers.

Ethics
The Columbia University Medical Center (CUMC) Institutional Review Board (IRB) will provide ethical oversight for the study. Ethical approval for this study has been granted from the CUMC IRB (Protocol Number: IRB-AAAN5869).

Publications
The final results from the study will be submitted for publication in a peer-reviewed journal. We will also disseminate our findings to the study site and study population.

Discussion
This study is one of the first to systematically develop and test an on-site bundled rapid HCV and rapid HIV testing strategy, complemented with post-test counseling and linkage to care services, to address the overlapping HIV and HCV epidemics among persons with SUDs. It is also novel in employing an efficacy-effectiveness-implementation hybrid design. We hypothesize that the bundled testing strategy will increase HIV and HCV testing rates and knowledge of infection status among persons with SUDs. On-site bundled rapid testing promises significant benefits in terms of both HCV and HIV-related outcomes. We anticipate that the bundled rapid testing strategy will considerably increase HCV testing rates among patients of SUD treatment programs, possibly in proportions similar to those observed during the multicenter trial of rapid HIV testing in such programs [25]. This has the potential to increase HCV case finding and reduce HCV transmission among patients of SUD treatment programs, through the adoption of safer injection and sexual practices. It may also promote treatment initiation, particularly in a context where numbers of patients may gain access to health insurance through the Affordable Care Act (ACA) and new, safe and effective treatments options for HCV have become available [42–45].

Bundled rapid testing may also provide important benefits in terms of HIV prevention and treatment. Since HIV and HCV often transmitted in the same needle-sharing and/or sexual networks, [70–77] testing positive for HCV may serve as a) an early warning system that a person is at a high risk of becoming infected with HIV and b) a system to allow the delivery of intensified risk reduction interventions and to encourage the adoption of protective behaviors (for example, needle exchange, partner reduction, and PrEP). In addition, knowledge of HCV status may improve clinical decisions related to HIV/AIDS care and treatment, including earlier diagnosis of co-infection, improved prevention of liver disease, and better management of side effects. The proposed study will address key barriers that prevent the broad diffusion of bundled rapid testing, including organizational and patient-level barriers, and provide preliminary data for future implementation research on the adoption of evidence-based practices in SUD treatment programs. In particular, it will yield insights about a multicomponent, multilevel intervention designed to foster the adoption and implementation of bundled rapid testing in such settings.

Trial status
The trial is at the planning stage, with the first six phases of the ADAPT-IT³ process already completed. Recruitment of study participants is tentatively scheduled to commence in March 2016.
### Abbreviations

#### Table 3 World Health Organization trial registration data set

| Item number | Item number | Description                                                                 | Addressed on page number |
|-------------|-------------|--------------------------------------------------------------------------------|--------------------------|
| 1           | 1           | Primary registry and trial-identifying number                                 | 2                        |
| 2           | 2           | Date of registration in primary registry                                      | 2                        |
| 3           | 3           | Secondary identifying numbers                                                | Not applicable           |
| 4           | 4           | Sources of monetary or material support                                       | 12                       |
| 5           | 5           | Primary sponsor                                                               | 12                       |
| 6           | 6           | Secondary sponsor(s)                                                          | Not applicable           |
| 7           | 7           | Contact for public queries                                                    | 1                        |
| 8           | 8           | Contact for scientific queries                                                | 1                        |
| 9           | 9           | Public title                                                                  | 1                        |
| 10          | 10          | Scientific title                                                              | Not applicable           |
| 11          | 11          | Countries of recruitment                                                      | 5                        |
| 12          | 12          | Health condition(s) or problem(s) studied                                     | 3                        |
| 13          | 13          | Intervention(s)                                                               | 6                        |
| 14          | 14          | Key inclusion and exclusion criteria                                          | 7                        |
| 15          | 15          | Study type                                                                    | 6 and 7                  |
| 16          | 16          | Date of first enrollment                                                      | 11                       |
| 17          | 17          | Target sample size                                                            | 9                        |
| 18          | 18          | Recruitment status                                                            | 11                       |
| 19          | 19          | Primary outcome(s)                                                            | 7                        |
| 20          | 20          | Key secondary outcome(s)                                                      | 7 and 8                  |
ACA: Affordable Care Act; ADAPT-ITT: Assessment-Decision-Administration-Production-Topical experts-Integration-Training-Testing; ADAPT-IT2: Assessment-Design-Administration-Production-Topical experts-Integration-Training-Testing-Translation; ARTAS: Anti-retroviral Treatment and Access to Services; CDC: Centers for Disease Control and Prevention; CDOP: chemical dependence outpatient program; CLIA: clinical laboratory improvement agreement; DOI: diffusion of innovation; EBI: evidence-based interventions; EIA: enzyme immunoassays; FQHC: federally qualified health center; HCV: hepatitis C virus; Hep-C CCM: Hepatitis C Care Coordination Model; HIV: human immunodeficiency virus; MTAA: methadone-to-abstinence ambulatory; PrEP: pre-exposure prophylaxis; PWID: person who injects drugs; RCT: randomized controlled trial; SOC: standard of care; SP: standardized patients; SUD: substance use disorder.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
JAF conceptualized and designed the study. JAF and TD serve as the Principal Investigators of this study. TD, DJF, and LRM were involved in the conception and design of the study and reviewed the manuscript. DCP, SS, AM, DH, and BS provided intellectual contributions to the study design and were involved in review of the manuscript. All authors read and approved the final manuscript.

Acknowledgements
The research reported in this publication is supported by NIDA under award number R34DA038530. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. We would like to thank members of the study sites who are supporting this study. Alissa Mallow was with Promesa Inc. of the Acacia Network at the time of submission.

Author details
1. Department of Health Policy and Management, Mailman School of Public Health, Columbia University, New York, USA. 2. Robert F. Wagner Graduate School of Public Service, New York University, New York, USA. 3. Mount Sinai Beth Israel; Ichan School of Medicine at Mount Sinai, New York, USA. 4. College of Nursing, New York University, New York, USA. 5. Montefiore Health System, New York, USA, New York, USA. 6. Department of Sociomedical Sciences, Mailman School of Public Health, Columbia University, New York, USA. 7. Department of Healthcare Policy and Research, Weill Cornell Medical College, New York, USA. 8. Division of Biostatistics, Department of Public Health Sciences, Miller School of Medicine, University of Miami, Miami, USA.

Received: 4 August 2015 Accepted: 10 February 2016
Published online: 03 March 2016

References
1. Centers for Disease Control and Prevention: HIV in the united States: At A Glance. http://www.cdc.gov/hiv/statistics/basics/ataglance.html. Accessed 12 June 2015.
2. Centers for Disease Control and Prevention: The ABCs of hepatitis. http://www.cdc.gov/hepatitis/ResourcesProfessionals/PDFs/ABCTable.pdf. Accessed 21 October 2012.
3. Armstrong GL, Wasley AM, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705–14.
4. Soriano V, Vispo E, Labarga P, Medrano J, Barreiro P. Viral hepatitis and HIV co-infection. Antiviral Res. 2010;85:303–15.
5. Thomas DL. The Challenge of Hepatitis C in the HIV-infected Person. Annu Rev Med. 2008;59:473–85.
6. Abuse S. Administration MHS. Center for Behavioral Health Statistics and Quality. The NSDUH Report: HIV/AIDS and Substance Use. 2010.
7. Amor JS, Garfein RS, Ahdieh-Grant L, Armstrong GL, Quellet LL, Latka MH, et al. Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004. Clin Infect Dis. 2008;46:1852–8.
8. Schaefer M, Heinz A, Backmund M. Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules? Addiction. 2004;99:1167–75.
9. Scheinmann R, Hagan H, Lelutu-Weinberger C, Stern R, Des Jarlais DC, Flom PL, et al. Non-injection drug use and Hepatitis C Virus: a systematic review. Drug Alcohol Depend. 2007;891–12.
10. Centers for Disease Control and Prevention: Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 U.S. dependent areas—2011. http://www.cdc.gov/hiv/library/reports/surveillance/. Accessed 14 March 2014.
11. Denniston MM, Kleven RM, McQuillan GM, Jiles RB. Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C. National Health and Nutrition Examination Survey 2001-2008. Hepatology. 2012;55:1652–61.
12. Department of Health and Human Services (DHHS): Combating the Silent Epidemic of Viral Hepatitis: Action Plan for the Prevention, Care & Treatment of Viral Hepatitis. http://www.hhs.gov/ash/initiatives/hepatitis/. Accessed 9 June 2015.
13. Ly KN, Xing J, Kleven RM, Jiles RB, Ward JW, Holmberg SD. The Increasing Burden of Mortality From Viral Hepatitis in the United States Between 1999 and 2007. Ann Intern Med. 2012;156:271–8.
14. Centers for Disease Control and Prevention: Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Morb Mortal Wkly Rep. 1998;47(19):1–39.
15. Centers for Disease Control and Prevention. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR. 2006;55(14):1–17.
16. Strauss SM, Astone J, Vassilev ZP, Des Jarlais DC, Hagan H. Gaps in the drug-free and methadone treatment program response to Hepatitis C J. Subst Abuse Treat. 2003;24:291–7.
17. Abraham AJ, O’Brien LA, Knudsen HK, Bride BE, Smith GR, Roman PM. Patient characteristics and availability of onsite non-rapid and rapid HIV testing in US substance use disorder treatment programs. J Subst Abuse Treat. 2013;44:120–5.
18. Brown LS, Kritz S, Goldsmith RJ, Bini EJ, Robinson J, Alderson D, et al. Health services for HIV/AIDS, HCV, and sexually transmitted infections in substance abuse treatment programs. Public Health Rep. 2007;122:441–51.
19. Campsmith ML, Rhodes PH, Hall HI, Green TA. Undiagnosed HIV prevalence among adults and adolescents in the United States at the end of 2006. J Acquir Immune Defic Syndr. 2010;53:619–24.
20. D’Aunno T, Polack HA, Jiang L, Metsch LR, Friedman PD. HIV Testing in the Nation’s Opioid Treatment Programs, 2005–2011. The Role of State Regulations. Health Serv Res. 2014;49(2):320–48.
21. Frimpong JA, D’Aunno T, Jiang L. Determinants of the Availability of Hepatitis C Testing Services in Opioid Treatment Programs: Results From a National Study. Am J Public Health. 2014;104(6):75–82.
22. Bini EJ, Kritz S, Brown LS, Robinson J, Alderson D, Rotrosen J. Barriers to providing health services for HIV/AIDS, hepatitis C virus infection and sexually transmitted infections in substance abuse treatment programs in the United States. J Addict Dis. 2011;30:98–109.
23. Frimpong JA. Missed opportunities for hepatitis C testing in opioid treatment programs. Am J Public Health. 2013;103:1028–30.
24. Umbricht-Schneider A, Ginn DH, Pabst KM, Bigelow GE. Providing medical care to methadone clinic patients: referral vs on-site care. Am J Public Health. 1994;84:207–10.
25. Metsch LR, Feaster DJ, Gooden L, Matheson T, Mandler RN, Haynes L, et al. Implementing Rapid HIV Testing With or Without Risk-Reduction Counseling in Drug Treatment Centers: Results of a Randomized Trial. Am J Public Health. 2012;102:1160–7.
26. Drobnik A, Judd C, Banach D, Egger J, Konty K, Rude E. Public health implications of rapid hepatitis C screening with an oral swab for community-based organizations serving high-risk populations. Am J Public Health. 2011;101:2151–5.
27. Franco-Paredes C, Tellez J, del Rio C. Rapid HIV testing: a review of the literature and implications for the clinician. Curr HIV/AIDS Rep. 2006;3:169–75.
28. Grusky O, Roberts KJ, Swanson AN. Failure to return for HIV test results: a pilot study of three community testing sites. J Int Assoc Physicians AIDS Care (Chic). 2007;6:47–55.
29. Sullivan PS, Lansky A, Drake A. Failure to return for HIV test results among persons at high risk for HIV infection: results from a multisite interview project. J Acquir Immune Defic Syndr. 2004;35:511–8.
30. Schwartz RP, Stitzer ML, Feaster DJ, Korthuis PT, Alvanza AAH, Winhusen TM, et al. HIV rapid testing in drug treatment: comparison across treatment modalities. J Subst Abuse Treat. 2013;44:369–74.
57. Rogers EM. Diffusion of innovations. 5th ed. New York, NY: Free Press; 2003.
58. Greenhalgh T, Robert G, Macfarlane F, Bate P, Kyriakidou O. Diffusion of innovations in service organizations: systematic review and recommendations. Milbank Q. 2004;82:581–629.
59. Lehman WE, Simpson DD, Knight DK, Flynn PM. Integration of treatment innovation planning and implementation: strategic process models and organizational challenges. Psychol Addict Behav. 2011;25:252–61.
60. Hagan H, Campbell J, Thiede H, Strathdee S, Oueller L, Kapadia F, et al. Self-reported hepatitis C virus antibody status and risk behavior in young injectors. Public Health Rep. 2006;121:710–9.
61. Network/Promesa A. Behavioral Health Services. http://www.acacianetwork.org/behavioral-health/. Accessed 22 June 2015.
62. Centers for Disease Control and Prevention. Revised guidelines for HIV counseling, testing, and referral. Morb Mortal Wky Rep. 2001;50(19):58–58.
63. Craw JA, Gardner LI, Marks G, Rapp RC, Bossart J, Duffus WA, et al. Brief strengths-based case management promotes entry into HIV medical care: results of the antiretroviral treatment access study-J. J Acquir Immune Defic Syndr. 2008;47:597–606.
64. Gardner LI, Metch LR, Anderson-Mahoney P, Loughlin AM, del Rio C, Strathdee S, et al. Efficacy of a brief case management intervention to link recently diagnosed HIV-infected persons to care. AIDS. 2005;19:423–31.
65. Larios SE, Masson CL, Shopshire MS, Hettema J, Jordan AE, McKnight C, et al. Education and counseling in the methadone treatment setting improves knowledge of viral hepatitis. J Subst Abuse Treat. 2014;46:258–31.
66. Masson CL, Delucchi KL, McKnight C, Hettema J, Khalili M, Min A, et al. A randomized trial of a hepatitis care coordination model in methadone maintenance treatment. Am J Public Health. 2013;103:e81–88.
67. Johnson TL, Tolliver JC, Mao L, Darmaswongu CU. Differences in outpatient care and treatment utilization for patients with HIV/HCV coinfection, HIV, and HCV monoinfection, a cross-sectional study. BMC Infect Dis. 2014;12:317.
68. Menich BS, Hewett PC, Gregory R, Hellinger S. Sexual Behavior and STI/ HIV Status Among Adolescents in Rural Malawi: An Evaluation of the Effect of Interview Mode on Reporting. Stud Fam Plann. 2008;39:321–34.
69. Robins JM, Rotnitzky A, Zhao LP. Analysis of semiparametric regression models for repeated outcomes in the presence of missing data. J Am Stat Assoc. 1995;90:106–21.
70. Suh T, Mandell W, Latkin C, Kim J. Social network characteristics and injecting HIV-risk behaviors among street injection drug users. Drug Alcohol Depend. 1997;47:837–43.
71. Koester S, Glanz J, Baron A. Drug sharing among heroin networks: implications for HIV and hepatitis B and C prevention. AIDS Behav. 2005;9:27–39.
72. Costenbader EC, Astone NM, Latkin CA. The dynamics of injection drug users’ personal networks and HIV risk behaviors. Addiction. 2006;101:1003–13.
73. De P, Cox J, Boivin JF, Plant RW, Jolly AM. The importance of social networks in their association to drug equipment sharing among injection drug users: a review. Addiction. 2007;102:1730–9.
74. Romano CM, de Canvalho-Mello IM, Jamal LF, de Melo FL, Iamarino A, Motoki M, et al. Social networks shape the transmission dynamics of hepatitis C virus. PLoS ONE. 2010;5:e11170.
75. Pilon R, Leonard L, Kim J, Vallee D, De Rubeis E, Jolly AM, et al. Transmission patterns of hepatitis B and hepatitis C virus among networks of people who inject drugs. PLoS ONE. 2011;6:e22245.
76. Yang C, Tobin K, Latkin C. Perceived sourcing of injection paraphernalia sharing networks among injection drug users in Baltimore, MD. AIDS Behav. 2011;15:61–21.
77. Havens JR, Lofwall MR, Frost SD, Duer CB, Leukefeld CG, Crosby RA. Individual and network factors associated with prevalent hepatitis C infection among rural Appalachian injection drug users. Am J Public Health. 2013;103:e44–52.